Adding Tafasitamab to Lenalidomide and Rituximab Prolongs PFS in Patients with Relapsed or Refractory Follicular Lymphoma By Ogkologos - December 18, 2025 204 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the inMIND study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer MOST POPULAR Making the most of your ‘eureka’ moment: getting from the science... September 22, 2021 New hormone treatment for advanced prostate cancer made available in England June 8, 2021 6 Things to Know About Regrowing and Caring for Your Hair... January 8, 2021 Targeted Therapy for Claudin-18.2 and Combined PD-1 and TIGIT Immunotherapy for... November 6, 2023 Load more HOT NEWS Worries About Medical Bills May Worsen Health Outcomes After Cancer Diagnosis FDA Grants Accelerated Approval to Dostarlimab-gxly for dMMR Endometrial Cancer Fructose Fuels Cancer Growth Indirectly, Lab Study Finds Νέα διαγνωστική μέθοδος για τον καρκίνο, με τη συμβολή της Microsoft
